[Comparison of curative effect of autologous peripheral blood stem cell transplantation versus bone marrow transplantation for acute leukemia].
To compare the clinical outcome of autologous peripheral blood stem cell transplantation (APBSCT) and autologous bone marrow transplantation (ABMT) in treatment of patients with acute leukemia in first remission, 41 patients received APBSCT, 17 patients received unpurged ABMT and 30 patients received purged ABMT. The results showed that hematopoietic recovery was significantly earlier after APBSCT than that after purged or unpurged ABMT. The 3-year disease-free survival (DFS), relapse rate (RR) and transplant-related mortality (TRM) for all patients of 3 groups were 51.7%, 41.7% and 6.8%, respectively. DFS and RR were significantly influenced by disease types (ALL or AML) and intervals between diagnosis and CR(1) or CR(1) and transplant. The main causes of transplant-related death were infection and hemorrhage. After APBSCT, DFS, RR and TRM were 48.4%, 43.9% and 4.9%, respectively, and did not differ significantly from those found in unpurged ABMT (47.1%, 45.6% and 11.8%) or purged ABMT (66.5%, 29.6% and 6.7%). It is concluded that the clinical outcome of APBSCT is similar to unpurged or purged ABMT but APBSCT allows faster recovery of hematopoiesis and needs less transfusion support.
Zhang
Yi-Zhuo
YZ
Department of Hematology, General Hospital of Chinese PLA, Beijing 100853. zhangyz8123@sina.com
Zhang
Bo-Long
BL
Yao
Shan-Qian
SQ
Liu
Hai-Chuan
HC
Lou
Fang-Ding
FD
Gao
Chun-Ji
CJ
Han
Xiao-Ping
XP
Wu
Xiao-Xiong
XX
Zhao
Yu
Y
Wang
Quan-Shun
QS
Jing
Yu
Y
Zhang
Miao
M
Jin
Hai-Jie
HJ
Shi
Zi-Jiang
ZJ
Da
Wan-Ming
WM
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000209:etiology / Q000401:mortality; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology / Q000401:mortality; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000628:therapy*; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology / Q000628:therapy; D007948:Leukemia, Monocytic, Acute / Q000473:pathology / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000628:therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology / Q000628:therapy; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous